ClinicalTrials.gg
Active, not recruitingNCT06110468Updated Nov 21, 2024

Physical Function, Health and Employment for People With Multiple Sclerosis

An interventional study of CoreDISTParticipation in Multiple Sclerosis, sponsored by Nordlandssykehuset HF. Active, not recruiting at 1 site in Norway. Open to participants aged 18 Years to 67 Years. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Nordlandssykehuset HF · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 67 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Multiple Sclerosis with a site in Norway — 2 open to participants now, 9 under way, 3 of them phase 3. Multiple Sclerosis · Norway.

Planned enrollment
31st of 43
114 · median 300
Started
2024
the only one that year
No phase
9 of 56
none open now
Registered
53rd of 56
by date
Lead sponsor
4 of 56
Nordlandssykehuset HF

Among the 56 studies in Multiple Sclerosis with a site in Norway, this one is the 31st largest by planned enrollment of the 43 interventional ones that give a count, is the only one that started in 2024, is one of 9 with no phase, and was the 53rd registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 56 studies in Multiple Sclerosis with a site in Norway are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 67 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Multiple Sclerosis with a site in Norway, or all of them as a file.
02

Study summary

Employment is low in people with MS, even when physical levels of functioning are high. The purpose of this study is to investigate if an individually tailored intervention combining individualized physiotherapy and work adaptation works better than usual care in terms of reducing barriers for work and improving levels of physical activity. The utility of the intervention will be investigated in terms of quality adjusted life years, long-term employment status and work-related costs.

Read the detailed description

Physiotherapy and physical activity interventions can reduce fatigue, improve balance, walking, HRQoL, and may improve neuromuscular and physical functioning in people with MS. However, these interventions lack coordination between health care levels and sectors and rarely address vital employment adaptations. Optimizing function and physical activity, when disability is low and neuroplasticity is optimal, can be valuable for maintaining work as levels of fatigue, mobility related symptoms and cognitive disturbances are associated with current employment.

People with an MS-diagnosis who reside in the North of Norway will be identified from patient lists from the neurological out-patient clinics in the participating hospitals. Upon the provision of written informed consent, all participants will undergo baseline testing prior to randomization into either the intervention or the control group. The intervention group will receive a physiotherapy assessment at the hospitals focusing on opportunities for change. Following this assessment they will participate in group training with a municipality physiotherapist twice weekly for six weeks followed by independent training for six weeks. In addition, both participants and their employers will get access to information films on opportunities for work adaptations and the importance of physical activity. Structured meetings with a specially trained employment consultant, the participant and their employer will be held to discuss possible work adaptations. Goals will be set and formally evaluated. Retests will be carried out at week 9, 16 and 52. Registry data on employment will be obtained from the Norwegian labour and welfare administration as a part of a cost-benefit analysis of the intervention.

03

Conditions studied

  • Multiple Sclerosis

Keywords

  • Physiotherapy
  • Employment
  • Physical activity
  • Health related quality of life
  • Cost-benefit
04

Who can participate

Ages eligible
18 Years to 67 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Multiple Sclerosis according to the McDonald's criteria
  • Extended Disability Status Scale (EDSS) 0-4
  • Being employed, part time or full time, may include various degrees of sick leave, disability pension or AAP.
  • Living in the participating 18 municipalities (Hammerfest, Alta, Senja, Målselv, Tromsø, Harstad, Narvik, Fauske, Bodø, Meløy, Vågan, Vestvågøy, Sortland, Hadsel, Rana, Vefsn, Alstadhaug, Brønnøy).

Exclusion criteria

Exclusion Criteria:

  • Pregnancy at enrolment.
  • Exacerbation of symptoms (i.e. relapse) within two weeks prior to enrolment.
  • Other serious conditions.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
114 participants (estimated)

Study arms

  • Experimental
    Intervention, CoreDISTParticpation

    Week 1-2: a)Videos for PwMS and employers on MS, possible work adaptations, physical activity (PA) and function. b)A meeting between PwMS and a work-consultant (WC). They will decide if the PwMS should discuss the work situation with their employer or if the WC and/or other professionals are needed. c)A clinical assessment with a trained MS-OP-PT to explore possibilities for optimalisation of movement. Week 3-8: a)A clinical assessment with the mPT building on previous assessment. Goal-setting for function and PA. b)CoreDIST-training in groups, 6 weeks, 1/week. indoors and 1/week outdoors. Independent training 1/week, CoreDISTvideos. c)A follow up meeting regarding work, evaluation of goals with mPT. New goal setting for week 10-15 Week 10-15, Self-administered, digitally supported home training: a)CoreDIST-videos 3x10 min/week b)Training of own choice including elements of high intensity and balance 2x30 minutes per week. c)Week 15: Evaluation of goals regarding work and PA

    Other: CoreDISTParticipation

  • No intervention
    Control, usual care

    Usual care (control group): These participants will continue with their regular routines and will be encouraged to obtain the national and MS-specific recommendation of 150-300 minutes of moderate physical activity or 75 minutes of high intensity physical activity per week or a combination of these, stay employed, continue medical treatment and seek any health care required, including physiotherapy.

Interventions

  • OtherCoreDISTParticipation

    CoreDISTparticipation is a multi-disciplinary individualized intervention that concurrently combine 1) providing PwMS and their employers with information on MS, possibilities for work-adaptations within the welfare system and the importance of physical activity 2) Structured goal-setting regarding reducing barriers for work and regarding physical function and activity for PwMS 3) A physiotherapy intervention focusing on improving the underlying prerequisites for balance and walking along with high intensive training and promotion of physical activity 4) structured evaluation and adjustment of goals.

06

What researchers measure

Primary outcomes

  1. Multiple Sclerosis Work Difficulties Questionnaire -23 Norwegian version

    How frequently individuals with MS perceive psychological/cognitive (11 items), physical (8 items), external, (4 items) barriers related to work, scored by a 5-point scale (0=best).

    Time frame: Baseline, 9, 16 and 52 weeks post baseline

  2. Levels of physical activity measured using ActiGraph wGT3x-BT monitors

    % of time in mild, moderate, intensive physical activity and sedate time

    Time frame: Participants will wear device for one week after testing at baseline and at 9, 16 and 52 weeks post baseline

Secondary outcomes

  1. 6 meter walk test

    Walking distance (meters) within six minutes

    Time frame: Baseline, 9, 16 and 52 weeks post baseline

  2. Step count using ActiGraph wGT3x-BT monitors

    Daily average number of steps

    Time frame: Participants will wear device for one week after testing at baseline and at 9, 16 and 52 weeks post baseline

  3. Fatigue Severity Scale -Norwegian version

    Self-report, 9 items: physical, social and cognitive effects of fatigue, scale:1-7 (high score indicates higher levels of fatigue).

    Time frame: Baseline, 9, 16 and 52 weeks post baseline

  4. Multiple Sclerosis Walking Scale-12

    Self-reported perception of walking, 12 items, score on a 5-point scale. Higher score indicate higher impact of MS on the individuals walking ability.

    Time frame: Baseline, 9, 16 and 52 weeks post baseline

  5. Mini Balance Evaluation Systems Test (MiniBESTest)

    Pro-and reactive balance, dual task and involving sit to stand, standing and walking, 14 items on a 3-point scale. Higher score indicate better performance.

    Time frame: Baseline, 9, 16 and 52 weeks post baseline

  6. Trunk Impairment Scale-modified Norwegian version (TISmodNV)

    Trunk control in sitting. 6 items, score on a 2- or 3-point scale, sum range 0-16 points. Higher score indicates higher levels of trunk control.

    Time frame: Baseline, 9, 16 and 52 weeks post baseline

  7. Postural control measured by AccuGait Optimized force platforms

    Measures postural control in standing, tandem, one-leg standing: postural sway of center of pressure.

    Time frame: Baseline, 9, 16 and 52 weeks post baseline

  8. European Quality of Life 5-Dimension (EQ-5D-5L) + Complementary questions

    Self-perceived HRQoL regarding five domains, and a VAS scale (0-100) on overall health. Complementary questions on sleep, wellbeing, emotions, social relations (advocated by the Norwegian Health Institute). Higher score indicate better self-perveived health.

    Time frame: Baseline, 9, 16 and 52 weeks post baseline

  9. Multiple Sclerosis Impact Scale 29-Norwegian version

    Self-perceived physical (13 items), psychological (9 items) impact on HRQoL, a 5-point scale. Higher score indicate increased impact of MS on the individuals day-to-day life.

    Time frame: Baseline, 9, 16 and 52 weeks post baseline

  10. Patient Global Impression of Change - physical activity and balance

    A global index that is used to rate the response of a condition to a therapy (transition scale). Higher score indicate improvement.

    Time frame: Baseline, 9, 16 and 52 weeks post baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2024, 9 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 9 months is below that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2023
First posted
Oct 31, 2023
StartActual
Mar 4, 2024
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2035
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06110468
Lead sponsor
Nordlandssykehuset HF
Collaborators
The Royal Norwegian Ministry of Health, University Hospital of North Norway, Nord University, UiT The Arctic University of Norway, Helgeland Hospital Trust, University of Tasmania, Norwegian Labour and Welfare Administration
Responsible party
Sponsor
First posted
Oct 31, 2023
Start date
Mar 4, 2024
Primary completion
Dec 2024 (estimated)
Completion
Dec 2035 (estimated)
Last update
Nov 21, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion